Search | Médecins Sans Frontières Access Campaign

12 results found
There is 1 active filter
Clear all filters
FDA priority review voucher

12 results found

Press release |

20 February 2019

Novartis secures FDA innovation prize for 30-year-old drug

Most recent Priority Review Voucher is a reminder of why Congress should reform the US government program to only reward companies for developing new and affordable drugs and vaccines for neglected diseases

Tags Intellectual property and trade FDA priority review voucher Novartis United States of America

Emmanuel arrived at the Nsanje district hospital with advanced HIV and related opportunistic infections cryptococcal meningitis and TB. He underwent a lumbar puncture to evacuate fluid creating pressure in the spinal column and brain caused by cryptococcal meningitis, Malawi 2017.

Press release |

30 August 2018

FDA adds new diseases to list of those eligible for flawed government incentive

US government program should only reward development of new drugs, vaccines for neglected diseases, and ensure access

Tags Tropical & neglected diseases cryptococcal meningitis FDA priority review voucher United States of America

Spotlight

Spotlight on: USFDA neglected disease PRV

Tags Intellectual property and trade Chagas diseasevisceral leishmaniasis (kala azar)Zika FDA priority review voucher

Kissing bugs (known as "vinchucas" in Bolivia and other Latin American countries) are usually found in houses in rural areas. These houses are made of adobe, a mixture of clay and straw. Photograph by Juan Renau

Press release |

31 August 2017

Chagas drug will be available in US

Tags Tropical & neglected diseases neglected diseases benznidazole FDA priority review voucher

Drug-resistant patient showing daily drug dose

Press release |

03 August 2017

Congress fails to boost treatment for neglected diseases

Tags Intellectual property and tradeResearch and development neglected diseases access to medicinesFDA priority review voucherinnovation

Press release |

07 June 2017

US Congressional Committee advances legislation that fails to fix FDA PRV program for neglected diseases

Tags Research and development neglected diseases access to medicinesFDA priority review voucherinnovation

Letter |

28 April 2017

Global health groups appeal to congress: Fix the FDA PRV for neglected diseases

Tags Tropical & neglected diseases neglected diseases access to medicinesFDA priority review voucherinnovation

Letter |

28 April 2017

Global Health Groups Appeal to Congress: Fix the FDA PRV for Neglected Diseases

Tags Research and development neglected diseases access to medicinesFDA priority review voucherinnovation

Treatment of a Kala azar-HIV co-infected patient lasts for almost a month. The duration of long admission impacts the individual and their families, often taking them away from their livelihoods or necessitating a caretaker’s presence. Pictured here is a patient with her daughter in MSF’s Kala azar-HIV ward in Patna, Bihar.

Press release |

02 March 2017

US Lawmakers fail to fix flawed PRV program intended to promote new medicines for neglected diseases

Tags Research and development neglected diseases access to medicinesFDA priority review voucherinnovation United States of America

Letter |

19 May 2016

Letter to US Congress - suggestions to fix the FDA PRV for neglected diseases

Tags Research and development neglected diseases access to medicinesFDA priority review voucherinnovationresearch and development (R&D)

Ubaldo Mendoza, 18, has initiated Chagas treatment in San Pedro Pochutlas health facility.

Press release |

12 December 2015

MSF Statement on KaloBios Plan to Raise Price Of Drug To Treat Chagas Disease

Tags Tropical & neglected diseases benznidazole FDA priority review voucher

Feature story |

08 December 2014

Congress should fix the priority review voucher program: MSF’s Rius explains

Tags Research and development neglected diseases access to medicinesFDA priority review voucherinnovationresearch and development (R&D)

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous

Novartis secures FDA innovation prize for 30-year-old drug

FDA adds new diseases to list of those eligible for flawed government incentive

Spotlight on: USFDA neglected disease PRV

Chagas drug will be available in US

Congress fails to boost treatment for neglected diseases

US Congressional Committee advances legislation that fails to fix FDA PRV program for neglected diseases

Global health groups appeal to congress: Fix the FDA PRV for neglected diseases

Global Health Groups Appeal to Congress: Fix the FDA PRV for Neglected Diseases

US Lawmakers fail to fix flawed PRV program intended to promote new medicines for neglected diseases

Letter to US Congress - suggestions to fix the FDA PRV for neglected diseases

MSF Statement on KaloBios Plan to Raise Price Of Drug To Treat Chagas Disease

Congress should fix the priority review voucher program: MSF’s Rius explains